Stock listing

ASX:ARX Aroa Biosurgery Ltd Share Price

Home listing (ASX) of Aroa Biosurgery Ltd

Follow Aroa Biosurgery Ltd into a list and get an email when it puts out news.

Share price · ASX:ARX

$0.485 AUD -0.020 (-4.0%)

Close on Nov 20, 2026

Past year -26.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.480 – $0.505 AUDNov 20, 2026
Volume
192,342 sharesNov 20, 2026
Market cap
$170.1M AUDAt the close on Nov 20, 2026 · price × 350.7M shares outstanding
52-week range
$0.465 – $0.775 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$112,115 AUDMedian day 131,185 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Aroa Biosurgery Ltd logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:ARX · Home$0.485 AUD-0.020 (-4.0%)192,342$0.495$0.505$0.480$0.505Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:ARX · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.485-0.020-4.0%$0.495$0.505$0.480192,342
$0.505+0.013+2.6%$0.500$0.510$0.490237,726
$0.492+0.012+2.5%$0.490$0.500$0.480313,072
$0.480-0.020-4.0%$0.510$0.510$0.480185,276
$0.500-0.010-2.0%$0.505$0.510$0.500846,693
$0.510+0.015+3.0%$0.500$0.510$0.49076,081
$0.495-0.015-2.9%$0.510$0.510$0.49074,287
$0.510+0.005+1.0%$0.505$0.515$0.50078,647
$0.505-0.025-4.7%$0.530$0.530$0.495149,591
$0.530+0.040+8.2%$0.495$0.530$0.465553,672
$0.490+0.005+1.0%$0.515$0.515$0.49064,693
$0.485-0.005-1.0%$0.500$0.510$0.485211,923
$0.490+0.005+1.0%$0.500$0.520$0.485248,655
$0.485-0.065-11.8%$0.550$0.550$0.485752,130
$0.550+0.015+2.8%$0.535$0.550$0.515203,047
$0.535+0.010+1.9%$0.530$0.535$0.515120,702
$0.525+0.005+1.0%$0.520$0.525$0.51557,326
$0.520-0.005-1.0%$0.530$0.530$0.52010,462
$0.525-0.015-2.8%$0.535$0.540$0.51589,312
$0.540+0.015+2.9%$0.530$0.545$0.52599,347
$0.525+0.015+2.9%$0.510$0.530$0.510123,081
$0.5100.0000.0%$0.510$0.510$0.50575,891
$0.5100.0000.0%$0.505$0.510$0.50593,948
$0.5100.0000.0%$0.495$0.510$0.495186,130
$0.510-0.030-5.6%$0.550$0.550$0.510197,026
$0.540+0.015+2.9%$0.515$0.540$0.490141,237
$0.525+0.025+5.0%$0.500$0.525$0.50092,107
$0.500-0.005-1.0%$0.510$0.510$0.4952,009,819
$0.505-0.015-2.9%$0.530$0.530$0.500122,781
$0.5200.0000.0%$0.550$0.550$0.520122,371
$0.520-0.015-2.8%$0.535$0.535$0.515243,140
$0.535+0.035+7.0%$0.515$0.540$0.515259,547
$0.500+0.005+1.0%$0.510$0.510$0.500460,913
$0.495+0.005+1.0%$0.500$0.525$0.495887,964
$0.4900.0000.0%$0.500$0.500$0.475193,991
$0.490-0.035-6.7%$0.500$0.505$0.490417,860
$0.525+0.035+7.1%$0.500$0.525$0.480590,468
$0.490-0.010-2.0%$0.490$0.505$0.490203,244
$0.500-0.010-2.0%$0.505$0.510$0.495135,951
$0.510-0.015-2.9%$0.525$0.525$0.510109,162
$0.525-0.005-0.9%$0.540$0.545$0.5255,128
$0.530+0.005+1.0%$0.520$0.530$0.520193,745
$0.525+0.005+1.0%$0.540$0.545$0.515126,419
$0.520-0.010-1.9%$0.540$0.540$0.515163,464
$0.5300.0000.0%$0.540$0.550$0.53040,686
$0.530-0.010-1.9%$0.545$0.550$0.52526,695
$0.540-0.020-3.6%$0.555$0.555$0.54017,385
$0.560+0.005+0.9%$0.550$0.560$0.535200,729
$0.555+0.005+0.9%$0.550$0.555$0.535423,133
$0.550+0.015+2.8%$0.530$0.550$0.515257,355
$0.535-0.010-1.8%$0.540$0.550$0.53524,698
$0.545+0.005+0.9%$0.540$0.550$0.53046,843
$0.540-0.020-3.6%$0.560$0.560$0.54055,435
$0.560+0.005+0.9%$0.555$0.560$0.55033,040
$0.555+0.015+2.8%$0.550$0.560$0.54083,651
$0.5400.0000.0%$0.550$0.550$0.5401,784
$0.540-0.010-1.8%$0.545$0.550$0.540113,354
$0.550-0.005-0.9%$0.560$0.560$0.54585,927
$0.555-0.010-1.8%$0.560$0.560$0.55071,026
$0.565+0.010+1.8%$0.570$0.575$0.555349,870
$0.555-0.005-0.9%$0.580$0.580$0.555121,789
$0.560-0.005-0.9%$0.570$0.575$0.56047,151
$0.565-0.010-1.7%$0.575$0.575$0.555178,273
$0.575+0.005+0.9%$0.570$0.580$0.56551,895
$0.570-0.010-1.7%$0.580$0.580$0.570175,560
$0.5800.0000.0%$0.595$0.595$0.575234,963

Splits

2 splits since 2016 · ASX:ARX · every price before a split is adjusted for it

DayRatioWhat
2-for-1Split
1-for-500Consolidation
Ticker
ASX:ARX
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
ASX
Currency
AUD

What changed lately

Latest news

AROA Appoints Mark Dunwoodie as CFO

Nov 2, 2026

Closed $0.49 (+1.0%) on Nov 3, 2026

Molnlycke to Co-promote Endoform In the US

Oct 15, 2026

Closed $0.51 (-5.6%) on Oct 16, 2026

Investor Presentation - Symphony RCT

Oct 11, 2026

Closed $0.505 (-2.9%) on Oct 12, 2026

Invite to Investor Webinar on Symphony RCT

Oct 6, 2026

Closed $0.535 (+7.0%) on Oct 7, 2026

Change in substantial holding

Oct 6, 2026

Closed $0.50 (+1.0%) on Oct 6, 2026

All Aroa Biosurgery Ltd news

Aroa Biosurgery Ltd on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
35 in the last 12 months · 81 in all · newest Nov 9, 2026 · oldest 2020
Decks
39 decks · latest Oct 12, 2026

Where Aroa Biosurgery Ltd is listed

ListingExchangeCountryCurrency
ASX:ARX · Home listing · This pageASXAustraliaAUD
OTC:AROAFOTCUnited StatesUSD

Valuation

P/E 40.9× against a median of 8.5×: 5th lowest of 6 Medical devices & supplies companies shown. Statements: Year to Mar 31, 2026 · price Nov 20, 2026

Enterprise value
$152.8M AUD
P/E
40.9×
EV/sales
1.7×
EV/EBITDA
16.9×
Price/book
2.1×
Gross margin
86.3%
Operating margin
4.7%
Net margin
4.5%
Debt to equity
0.1×
Beta
No index for this market yet

Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Aroa Biosurgery Ltd · ASX:ARXUS$112.6MUS$101.1M40.9×1.7×16.9×2.1×4.5%0.1×n/a
Mercator Medical SA · GPW:MRCUS$123.9MUS$87.98M7.6×0.6×4.5×0.5×10.7%0.0×n/a
Edap Tms SA · NASDAQ:FOCLUS$123.2MUS$103.0Mn/a1.3×n/a3.4×−47.0%1.0×1.17
St.Shine Optical Co., Ltd. · TPEX:1565US$117.8MUS$48.97M8.5×0.4×2.0×0.6×11.1%0.0×n/a
MediNice SA · GPW:ICEUS$114.5MUS$113.6Mn/an/an/a5.5×n/a0.0×n/a
Allgens Medical Technology Co. Ltd. Class A · SSE:688613US$112.4M−US$36.15M94.7×−1.1×n/a0.5×3.5%0.0×n/a
Pulmonx Corporation · NASDAQ:LUNGUS$111.9MUS$97.15Mn/a1.1×n/a3.3×−47.9%1.1×1.95
Laxmi Dental Ltd. · NSE:LAXMIDENTLUS$111.4MUS$110.1M31.9×3.5×20.4×3.9×11.0%0.1×n/a
Interojo Inc. · KRX:119610US$106.3MUS$84.65M8.0×0.9×3.4×0.9×14.3%0.0×n/a
Onward Medical N.V. · EURONEXT:ONWDUS$106.1MUS$31.75Mn/a5.3×n/a1.3×−771.8%0.2×n/a
Orthocell Ltd · ASX:OCCUS$102.8MUS$74.57Mn/a9.9×n/a4.5×−122.0%0.1×n/a
Median of the othersUS$112.2MUS$86.31M8.5×1.1×4.0×2.3×3.5%0.0×1.56

Forecasts

Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
1.08 AUD · Analysts' mean
EPS, year to Mar 2027
0.016 · 3 analysts
Revenue, year to Mar 2027
120.6M · 3 analysts

Team and board

Officers

OfficerRole
Brian WardFounder and Chief Executive Officer
Mark DunwoodieCFO
Rod StanleyChief Operating Officer
James AgnewJoint Company Secretary
Barnaby C. H. MayChief Scientific Officer
Michael Lynskey
Yasmin WinchesterChief of Technical Operations

Board

DirectorRole
Jim McLeanIndependent, Non-Executive Director and Chair
Brian WardFounder and Chief Executive Officer
Catherine MohrNon-Executive Director
Darla HuttonIndependent, Non-Executive Director
Paul ShearerIndependent, Non-Executive Director
Phil McCaw B.B.S.Non-Executive Director

Events

Next results
Nov 24, 2026 (expected)
QuarterResultsShare move
Q2 2026Nov 24, 2025−5.2%
Q4 2025May 28, 2025+14.0%
Q2 2025Nov 25, 2024+2.3%
Q3 2022Mar 31, 2022+4.0%
Q1 2022Sep 12, 20210.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck26 slidesOct 12, 2026
Technical Presentation (October 2026)Technical23 slidesOct 7, 2026
Shareholder Meeting (August 2026)Shareholder meeting11 slidesAug 19, 2026
FY2026 Earnings PresentationEarnings31 slidesMay 26, 2026
FY2026 Earnings PresentationEarnings30 slidesMay 26, 2026
Corporate Update (February 2026)Corporate update10 slidesFeb 3, 2026
H1 FY26 Earnings PresentationEarnings70 slidesNov 25, 2025
Q2 FY26 Earnings PresentationEarnings25 slidesOct 16, 2025
Shareholder Meeting (August 2025)Shareholder meeting22 slidesAug 20, 2025
Q1 FY26 Earnings PresentationEarnings24 slidesJul 29, 2025
All 39 decks
DeckKindSlidesDate
FY2025 Earnings PresentationEarnings32 slidesMay 29, 2025
Q4 FY2025 Earnings PresentationEarnings10 slidesApr 29, 2025
Q2 FY25 Earnings PresentationEarnings16 slidesJan 29, 2025
H1 FY25 Earnings PresentationEarnings52 slidesNov 26, 2024
Q2 FY25 Earnings PresentationEarnings13 slidesOct 22, 2024
Q1 FY25 Earnings PresentationEarnings23 slidesJul 24, 2024
Shareholder Meeting (July 2024)Shareholder meeting21 slidesJul 23, 2024
FY2024 Earnings PresentationEarnings27 slidesMay 21, 2024
Q4 FY24 Earnings PresentationEarnings10 slidesApr 30, 2024
Q3 FY24 Earnings PresentationEarnings9 slidesJan 30, 2024
H1 FY24 Earnings PresentationEarnings24 slidesNov 28, 2023
Bell Potter Healthcare Conference November 2023Conference14 slidesNov 14, 2023
Q2 FY24 Earnings PresentationEarnings15 slidesOct 31, 2023
Shareholder Meeting (August 2023)Shareholder meeting29 slidesAug 3, 2023
Investor Presentation (June 2023)Investor deck72 slidesJun 1, 2023
FY2023 Earnings PresentationEarnings20 slidesMay 31, 2023
Q4 FY23 Earnings PresentationEarnings13 slidesApr 27, 2023
Corporate Update (January 2023)Corporate update15 slidesJan 31, 2023
H1 FY23 Earnings PresentationEarnings14 slidesNov 29, 2022
H1 FY23 Earnings PresentationEarnings14 slidesOct 25, 2022
Shareholder Meeting (August 2022)Shareholder meeting17 slidesAug 10, 2022
FY2022 Earnings PresentationEarnings15 slidesMay 24, 2022
Investor Presentation (April 2022)Investor deck29 slidesApr 26, 2022
Bell Potter Healthcare Conference 2021Conference12 slidesNov 9, 2021
Investor Presentation (July 2021)Investor deck41 slidesJul 29, 2021
Shareholder Meeting (July 2021)Shareholder meeting8 slidesJul 20, 2021
Investor Day (July 2021)Investor day71 slidesJul 5, 2021
FY2021 Earnings PresentationEarnings20 slidesMay 25, 2021
IPO Roadshow (July 2020)IPO roadshow34 slidesJul 30, 2020

Open Decks

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue92.3M77.0M63.4M59.3M36.9M20.5M24.3M21.8M9.66M0
Cost of revenue12.7M11.0M9.26M9.25M8.72M6.26M6.33M8.04M5.45M54.0K
Gross profit79.6M66.0M54.1M50.1M28.2M14.3M17.5M13.7M4.21M0
Research and development7.05M8.69M8.40M9.93M7.76M5.90M4.48M4.07M2.89M
Selling, general and administrative63.6M60.9M597.6K47.7M28.5M20.0M16.7M11.9M3.90M786.7K
Operating income4.36M-8.13M-9.79M-2.91M-6.98M-10.3M-2.83M-179.3K-2.24M-842.8K
Depreciation and amortization4.67M4.50M4.09M3.50M2.95M3.05M2.61M1.93M681.8K1.77K
EBITDA9.03M-3.62M-5.70M593.9K-4.03M-7.28M-219.5K1.75M-1.56M-841.0K
Interest expense420.3K439.7K1.16M344.4K1.08M400.6K228.0K2.57M62.8K0
Income before tax3.85M-2.95M-9.56M-359.4K-7.68M-17.5M-5.85M-2.84M-1.46M-722.7K
Income tax-310.1K511.6K184.4K11.2K116.2K98.2K-191.9K-3.74M-284.5K0
Net income4.16M-3.47M-9.75M-370.7K-7.79M-17.6M-5.66M896.3K-1.18M-722.7K
Earnings per share, basic0.01-0.01-0.03-0.00-0.02-0.06-0.020.00-0.00

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents17.5M7.26M10.6M8.93M5.73M32.5M41.5M4.28M3.65M800.1K
Short-term investments5.06M12.9M17.2M34.1M47.6M1.45M944.7K9.60K37.0K37.0K
Receivables33.8M14.8M24.1M13.4M16.0M6.60M7.16M5.25M2.48M8.53K
Inventory5.01M7.52M7.43M4.52M3.70M3.31M3.88M2.57M1.68M
Current assets64.4M62.0M63.3M73.1M74.2M44.8M17.4M12.6M8.89M922.1K
Property, plant and equipment21.5M22.2M20.6M15.4M12.7M8.73M6.09M5.42M5.41M
Goodwill4.61M5.03M5.08M5.18M5.15M5.08M5.36M5.32M5.32M
Total assets100.5M98.9M101.9M109.1M104.7M73.1M44.5M38.0M14.3M6.52M
Accounts payable4.88M1.51M1.57M1.79M1.24M679.3K1.16M435.9K674.3K136.3K
Current liabilities13.5M9.36M8.73M7.41M6.24M14.0M6.13M7.83M2.25M175.3K
Long-term debt01.12M431.0K1.39M
Total debt5.31M5.83M6.82M7.07M5.83M15.4M10.8M1.09M1.52M
Total liabilities17.7M14.3M14.8M13.7M11.3M19.4M19.7M26.4M12.5M234.7K
Shareholders' equity82.7M84.6M87.1M95.4M93.4M53.7M62.9M11.5M1.77M6.28M
Shares outstanding363.5M344.9M343.8M342.9M342.2M300.4M300.1M300.1M300.1M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations9.37M-2.33M-6.76M-3.53M-10.7M-5.01M1.58M-6.54K-2.80M-737.1K
Capital spending-985.5K-3.36M-3.23M-7.12M-4.53M-1.38M-1.78M-1.53M-1.55M-40.9K
Free cash flow8.39M-5.69M-10.00M-10.7M-15.4M-1.38M-199.5K-1.54M-4.36M-777.9K
Cash from investing3.80M273.5K9.31M6.79M-32.4M-21.5M-1.78M-3.46M4.91M339
Cash from financing-1.55M-1.34M-948.4K-471.8K35.0M34.1M-364.9K3.86M410.2K858.9K
Dividends paid-0-18.2M
Share buybacks-1.35M-1.13M-958.5K-2.06M-3.97M296.0K8.87M48.0K917.5K
Change in cash10.3M-3.21M1.82M3.16M-8.57M10.6M-549.9K631.9K2.52M120.4K

Open Financials

Filings

FilingDateTypeFiled with
US CMS Confirms Symphony Outpatient Reimbursement RateNov 8, 2026GuidanceASX
Aroa Biosurgery H1 FY27 Results & Investor EventNov 3, 2026ResultsASX
AROA Appoints Mark Dunwoodie as CFONov 2, 2026Management or board changeASX
Change in substantial shareholding for ARXOct 18, 2026Other filingsASX
Molnlycke to Co-promote Endoform In the USOct 15, 2026Other filingsASX
Notification of cessation of securities - ARXOct 12, 2026FinancingASX
Investor Presentation - Symphony RCTOct 11, 2026Other filingsASX
Invite to Investor Webinar on Symphony RCTOct 6, 2026Other filingsASX
Investor Presentation - MASTRR Interim AnalysisOct 6, 2026Operations updateASX
Change in substantial holdingOct 6, 2026Ownership change noticeASX
All 74 filings
FilingDateTypeFiled with
Symphony Significantly Improves DFU HealingOct 4, 2026Other filingsASX
Invite to Investor Webinar on MASTRR Interim AnalysisSep 28, 2026Other filingsASX
Myriad MASTRR Study Reports Low Infection RatesSep 3, 2026Operations updateASX
Change of Director's Interest Notice - BWAug 27, 2026Ownership change noticeASX
Notification regarding unquoted securities - ARXAug 27, 2026Notification letterASX
Final Director's Interest Notice - JDAug 20, 2026Ownership change noticeASX
Results of Annual General MeetingAug 19, 2026Meeting outcomeASX
CEO Presentation - AGMAug 18, 2026Other filingsASX
Chairman's Address - AGMAug 18, 2026Meeting outcomeASX
Notification of cessation of securities - ARXAug 11, 2026FinancingASX
Notification regarding unquoted securities - ARXAug 11, 2026Other filingsASX
Change in substantial shareholding for ARXAug 6, 2026Other filingsASX
Notification regarding unquoted securities - ARXJul 27, 2026Other filingsASX
Commercial Leadership AppointmentsJul 27, 2026Management or board changeASX
FY26 Full Year Results PresentationMay 25, 2026ResultsASX
FY26 Appendix 4E and Full Year ResultsMay 25, 2026ResultsASX
ARX FY26 Preliminary ResultsApr 29, 2026ResultsASX
Symphony Randomised Control Trial CompleteMar 29, 2026Other filingsASX
AROA Business Update PresentationFeb 2, 2026GuidanceASX
AROA Business UpdateFeb 2, 2026Operations updateASX
Aroa Biosurgery H1 FY26 ResultsNov 24, 2025ResultsASX
Appendix 4D and Half Year ReportNov 24, 2025Interim reportASX
September 2025 Quarterly Report and Appendix 4COct 15, 2025Quarterly reportASX
June 2025 Quarterly Report and Appendix 4CJul 28, 2025Quarterly reportASX
FY25 Full Year Results PresentationMay 28, 2025ResultsASX
FY25 Appendix 4E and Full Year ResultsMay 28, 2025ResultsASX
March 2025 Quarterly Report and Appendix 4CApr 28, 2025Quarterly reportASX
December 2024 Quarterly Report and Appendix 4CJan 28, 2025Quarterly reportASX
Aroa Half Year Results PresentationNov 25, 2024Interim reportASX
Aroa Biosurgery Half Yearly Results H1 FY25Nov 25, 2024ResultsASX
September 2024 Quarterly Report and Appendix 4COct 21, 2024Quarterly reportASX
June 2024 Quarterly Report and Appendix 4CJul 23, 2024Quarterly reportASX
FY24 Full Year Results PresentationMay 20, 2024ResultsASX
FY24 Appendix 4E and Full Year ResultsMay 20, 2024ResultsASX
March 2024 Quarterly Report and Appendix 4CApr 29, 2024Quarterly reportASX
December 2023 Quarterly Report and Appendix 4CJan 29, 2024Quarterly reportASX
Aroa Biosurgery Half Yearly Results H1 FY24Nov 27, 2023ResultsASX
September 2023 Quarterly Report and Appendix 4COct 30, 2023Quarterly reportASX
June 2023 Quarterly Report and Appendix 4CJul 30, 2023Quarterly reportASX
FY23 Full Year Results PresentationMay 30, 2023ResultsASX
FY23 Appendix 4E and Full Year ResultsMay 30, 2023ResultsASX
March 2023 Quarterly Report and Appendix 4CApr 26, 2023Quarterly reportASX
AROA secures first FDA clearance for ENIVO systemApr 11, 2023Other filingsASX
December 2022 Quarterly Report and Appendix 4CJan 30, 2023Quarterly reportASX
Aroa Biosurgery Half Yearly Results H1 FY23Nov 28, 2022Interim reportASX
September 2022 Quarterly Report and Appendix 4COct 24, 2022Quarterly reportASX
June Quarterly Report and Appendix 4CJul 25, 2022Quarterly reportASX
FY22 Full Year Results PresentationMay 23, 2022ResultsASX
FY22 Appendix 4E and Full Year ResultsMay 23, 2022ResultsASX
March Quarterly Report and Appendix 4CApr 25, 2022Quarterly reportASX
December Quarterly Report and Appendix 4CJan 27, 2022Quarterly reportASX
Aroa Biosurgery Half Yearly Report H1 FY21Nov 24, 2021Interim reportASX
September Quarterly Report and Appendix 4COct 26, 2021Quarterly reportASX
Aroa delivers strong half, Myriad GPO winOct 5, 2021Other filingsASX
Investor PresentationJul 28, 2021Other filingsASX
Aroa Completes $47m Placement and Launches $5m SPPJul 28, 2021FinancingASX
Trading HaltJul 26, 2021Trading halt or suspensionASX
FY21 Full Year Results PresentationMay 24, 2021ResultsASX
Preliminary Final ReportMay 24, 2021ResultsASX
Aroa secures FDA clearance for new productApr 5, 2021Other filingsASX
S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021Other filingsASX
Aroa Half Year ResultsNov 25, 2020Interim reportASX
Aroa Biosurgery Secures FDA Clearance for SymphonyJul 30, 2020Other filingsASX
European Approval Received for MyriadJul 29, 2020Other filingsASX

Open Filings

Cap table

Built by 6ix from Aroa Biosurgery Ltd’s releases

Common shares
350,662,504
Fully diluted
350,662,504

Fully diluted

LineShares
Common shares350,662,504

Share count over time

CountShares
Nov 22, 2026350,662,504

Open Cap table

Shareholders

HolderSharesValueAs of
The Asia Pacific Small Company Series314KUS$126KJul 31, 2026
Commonwealth Australia/New Zealand Fund145KUS$58,208Jul 31, 2026
Dimensional VA International Small Portfolio37,311US$14,959Jul 31, 2026
First American Multi-Manager International Equity Fund35,869US$14,804Jun 30, 2026
Siit Screened World Equity Ex-Us Fund22,919US$11,461May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Barnaby C. H. MayChief Scientific Officer · Since at least May 2, 2025
Brian WardFounder and Chief Executive Officer · Since at least Nov 3, 2026
Catherine MohrNon-Executive Director · Since at least Nov 5, 2026
Darla HuttonIndependent, Non-Executive Director · Since at least Nov 5, 2026
James AgnewJoint Company Secretary · Since at least Nov 4, 2026
Jim McLeanIndependent, Non-Executive Director and Chair · Since at least Nov 5, 2026
Mark DunwoodieCFO · Since at least Nov 2, 2026
Michael LynskeyOfficer · Since at least Jul 27, 2026
Paul ShearerIndependent, Non-Executive Director · Since at least Nov 5, 2026
Phil McCaw B.B.S.Non-Executive Director · Since at least Nov 5, 2026
All 12 people
PersonSeat
Rod StanleyChief Operating Officer · Since at least Nov 4, 2026
Yasmin WinchesterChief of Technical Operations · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Aroa Biosurgery Ltd.